Preliminary, open-label, pilot study of add-on oral Δ9- tetrahydrocannabinol in chronic post-traumatic stress disorder

Clinical Drug Investigation

Volumn 34, Issue 8, 2014, Pages 587-591

  Roitman, Pablo ^a,b   Mechoulam, Raphael ^c   Cooper Kazaz, Rena ^d   Shalev, Arieh ^a,e  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Institute for Drug Research Hebrew University School of Pharmacy ^*  (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; CANNABINOID RECEPTOR AGONIST;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NIGHTMARE; OPEN STUDY; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REMISSION; SLEEP AROUSAL DISORDER; SLEEP QUALITY; SUBSTANCE ABUSE; TREATMENT OUTCOME; TREMOR; XEROSTOMIA; CHRONIC DISEASE; DREAM; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; RETROSPECTIVE STUDY; SELF REPORT; STRESS DISORDERS, POST-TRAUMATIC;

ADMINISTRATION, ORAL; ADULT; CANNABINOID RECEPTOR AGONISTS; CHRONIC DISEASE; DREAMS; DRONABINOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; SELF REPORT; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84904573718     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0212-3     Document Type: Article

References (27)

1. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr. 2009;14(1 Suppl 1):25-31.
2. Bonn-Miller MO, Vujanovic AA, Drescher KD. Cannabis use among military veterans after residential treatment for posttraumatic stress disorder. Psychol Addict Behav. 2011;25(3):485-91.
3. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58(3):389-462. (Pubitemid 44394908)
4. Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012;4(7-8):649-59.
5. Pierre JM. Psychosis associated with medical marijuana: risk vs. benefits of medicinal cannabis use. Am J Psychiatry. 2010; 167(5):598-9.
6. Musty RE, Rossi R. Effects of smoked Cannabis and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. J Cannabis Therapy. 2001;1:30.
7. Crippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24(7):515-23.
8. Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, et al. Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007;45(5):545-54. (Pubitemid 47294927)
9. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84-8.
10. Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoact Drugs. 2014;46(1):73-7.
11. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530-4. (Pubitemid 34851398)
12. Rabinak CA, Angstadt M, Sripada CS, Abelson JL, Liberzon I, Milad MR, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology. 2013;64:396-402.
13. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):6.
14. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75-90.
15. Guy GW. The Clinical Global Impression Scale. In: ECDEU assessment manual for psychopharmacology-revised. Bethesda; US Department of Health, Education and Welfare; 1976:pp 218-222.
16. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213. (Pubitemid 19144991)
17. Krakow B. Nightmare frequency in sexual assault survivors with PTSD. J Anxiety Disord. 2002;16(2):175-90. (Pubitemid 34580607)
18. Krakow B, Hollifield M, Schrader R, Koss M, Tandberg D, Lauriello J, et al. A controlled study of imagery rehearsal for chronic nightmares in sexual assault survivors with PTSD: a preliminary report. J Trauma Stress. 2000;13(4):589-609.
19. Guy GW. A phase 1, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannabis Ther 2003;3:31.
20. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349-53. (Pubitemid 44434985)
21. Haroutiunian S, Rosen G, Shouval R, Davidson E. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. J Pain Palliat Care Pharmacother. 2008;22(3):213-7.
22. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt Int. 2012;109(29-30):495-501.
23. Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;1(136):162-5.
24. Schierenbeck T, Riemann D, Berger M, Hornyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381-9.
25. Bremner JD, Southwick SM, Darnell A, Charney DS. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. Am J Psychiatry. 1996;153(3):369-75. (Pubitemid 26074712)
26. Ursano RJ, Zhang L, Li H, Johnson L, Carlton J, Fullerton CS, et al. PTSD and traumatic stress from gene to community and bench to bedside. Brain Res. 2009;26(1293):2-12.
27. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011;124(4):250-61.